BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

Thomas Gaisl; Chris D. Turnbull; Gerrit Weimann; Sigrun Unger; Rudolf Finger; Charles Xing; Peter A. Cistulli; Sophie West; Alan K.I. Chiang; Danny J. Eckert; John R. Stradling; Malcolm Kohler

doi:10.1183/13993003.01937-2021

BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

Thomas Gaisl, Chris D. Turnbull, Gerrit Weimann, Sigrun Unger, Rudolf Finger, Charles Xing, Peter A. Cistulli, Sophie West, Alan K.I. Chiang, Danny J. Eckert, John R. Stradling, Malcolm Kohler

College of Medicine and Public Health

Research output: Contribution to journal › Letter › peer-review

11 Citations (Scopus)

48 Downloads (Pure)

Abstract

To the Editor:

For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approve]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.

A promising target is pharmacological treatment increasing upper airway stability by activating the genioglossus muscle. Its activation by the central respiratory control system is importantly modified by mechanoreceptive reflex mechanisms operating locally in the upper airways and modulated by changes in pharyngeal pressure . It has been shown that genioglossus muscle activity and reflex modulation to changes in airway pressure are sleep stage dependent. Many OSA patients have apnoea-free intervals in which genioglossus muscle activity is only 25–40% higher compared with sleep phases with frequent obstructive apnoeas...

Original language	English
Article number	2101937
Number of pages	5
Journal	European Respiratory Journal
Volume	58
Issue number	5
DOIs	https://doi.org/10.1183/13993003.01937-2021
Publication status	Published - 1 Nov 2021

Keywords

obstructive sleep apnoea
BAY 2253651
Patient outcomes

Access to Document

10.1183/13993003.01937-2021Licence: CC BY-NC

Published versionFinal published version, 379 KBLicence: CC BY-NC

Cite this

Gaisl, T., Turnbull, C. D., Weimann, G., Unger, S., Finger, R., Xing, C., Cistulli, P. A., West, S., Chiang, A. K. I., Eckert, D. J., Stradling, J. R., & Kohler, M. (2021). BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN). European Respiratory Journal, 58(5), Article 2101937. https://doi.org/10.1183/13993003.01937-2021

@article{93d7d48a685144a483692bb21486ca18,

title = "BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)",

abstract = "To the Editor:For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approve]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.A promising target is pharmacological treatment increasing upper airway stability by activating the genioglossus muscle. Its activation by the central respiratory control system is importantly modified by mechanoreceptive reflex mechanisms operating locally in the upper airways and modulated by changes in pharyngeal pressure . It has been shown that genioglossus muscle activity and reflex modulation to changes in airway pressure are sleep stage dependent. Many OSA patients have apnoea-free intervals in which genioglossus muscle activity is only 25–40% higher compared with sleep phases with frequent obstructive apnoeas...",

keywords = "obstructive sleep apnoea, BAY 2253651, Patient outcomes",

author = "Thomas Gaisl and Turnbull, {Chris D.} and Gerrit Weimann and Sigrun Unger and Rudolf Finger and Charles Xing and Cistulli, {Peter A.} and Sophie West and Chiang, {Alan K.I.} and Eckert, {Danny J.} and Stradling, {John R.} and Malcolm Kohler",

year = "2021",

month = nov,

day = "1",

doi = "10.1183/13993003.01937-2021",

language = "English",

volume = "58",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "5",

}

Gaisl, T, Turnbull, CD, Weimann, G, Unger, S, Finger, R, Xing, C, Cistulli, PA, West, S, Chiang, AKI, Eckert, DJ, Stradling, JR & Kohler, M 2021, 'BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)', European Respiratory Journal, vol. 58, no. 5, 2101937. https://doi.org/10.1183/13993003.01937-2021

TY - JOUR

T1 - BAY 2253651 for the treatment of obstructive sleep apnoea

T2 - a multicentre, double-blind, randomised controlled trial (SANDMAN)

AU - Gaisl, Thomas

AU - Turnbull, Chris D.

AU - Weimann, Gerrit

AU - Unger, Sigrun

AU - Finger, Rudolf

AU - Xing, Charles

AU - Cistulli, Peter A.

AU - West, Sophie

AU - Chiang, Alan K.I.

AU - Eckert, Danny J.

AU - Stradling, John R.

AU - Kohler, Malcolm

PY - 2021/11/1

Y1 - 2021/11/1

N2 - To the Editor:For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approve]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.A promising target is pharmacological treatment increasing upper airway stability by activating the genioglossus muscle. Its activation by the central respiratory control system is importantly modified by mechanoreceptive reflex mechanisms operating locally in the upper airways and modulated by changes in pharyngeal pressure . It has been shown that genioglossus muscle activity and reflex modulation to changes in airway pressure are sleep stage dependent. Many OSA patients have apnoea-free intervals in which genioglossus muscle activity is only 25–40% higher compared with sleep phases with frequent obstructive apnoeas...

AB - To the Editor:For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approve]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.A promising target is pharmacological treatment increasing upper airway stability by activating the genioglossus muscle. Its activation by the central respiratory control system is importantly modified by mechanoreceptive reflex mechanisms operating locally in the upper airways and modulated by changes in pharyngeal pressure . It has been shown that genioglossus muscle activity and reflex modulation to changes in airway pressure are sleep stage dependent. Many OSA patients have apnoea-free intervals in which genioglossus muscle activity is only 25–40% higher compared with sleep phases with frequent obstructive apnoeas...

KW - obstructive sleep apnoea

KW - BAY 2253651

KW - Patient outcomes

UR - http://www.scopus.com/inward/record.url?scp=85121455189&partnerID=8YFLogxK

U2 - 10.1183/13993003.01937-2021

DO - 10.1183/13993003.01937-2021

M3 - Letter

C2 - 34531274

AN - SCOPUS:85121455189

SN - 0903-1936

VL - 58

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 5

M1 - 2101937

ER -

BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this